Methods of treating new-onset plaque type psoriasis using il-17 antagonists
AssigneeNovartis AG
InventorsAndreas Fasth, Jaime Oliver
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating new-onset plaque-type psoriasis patients and inhibiting the progression of structural damage in these patients, using Interleukin-17 (IL-17) antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating new-onset plaque-type psoriasis patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
Claims21
-16. (canceled)
A method of treating a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering to the patient about 150 mg-about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by about 150 mg-about 300 mg every four weeks.
A method of reducing the number of tissue resident memory cells in the lesional skin of a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering to the patient about 150 mg-about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by about 150 mg-about 300 mg every four weeks.
Dependencies are inferred from the claim text.